Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE.

By L. Rice. Journal of Infectious Diseases, 2008

2,118 citations recorded by the source corpus.

Subfields: Infectious Diseases, Molecular Biology, Molecular Medicine

View Paper: https://www.semanticscholar.org/paper/86b8fdb95696c5801b88ec137e12843f4a1b47a7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Infectious Diseases

In Molecular Biology

In Molecular Medicine

Citations in the corpus

Mobile Genetic Elements Associated with Antimicrobial Resistance (2018, background): “(the so-called ESKAPE group [1]) as well as Escherichia coli (giving the ESKAPEE group) (2); nonetheless, many of the MGE types described are of course broadly relevant to many other bacterial taxa.”
10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. (2013, background): “Infections caused by antibiotic-resistant bacteria, especially the “ESKAPE” pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species), cause significant morbidity and mortality [1, 2].”
Antimicrobial Resistance in ESKAPE Pathogens (2020, background): “aeruginosa, and Enterobacter species) pathogens (11) were designated “priority status””
ESKAPE pathogens: antimicrobial resistance, epidemiology, clinical impact and therapeutics (2024, neutral): “…in clinical medicine can be attributed to a specific group of pathogens that includes Enterococcus faecium , Staphylococcus aureus , Klebsiella pneumoniae , Acinetobacter baumannii , Pseudomonas aeruginosa and other members of the Enterobacterales group, called the ‘ESKAPE’ organisms 4 (Table 1).”
Emerging Strategies to Combat ESKAPE Pathogens in the Era of Antimicrobial Resistance: A Review (2019, background): “5% Hospital Acquired Infection (HAIs) in the world (Rice, 2008; Allegranzi et al., 2011; Ibrahim et al., 2012; Pendleton et al., 2013).”
Health care-associated infections – an overview (2018, background): “[42] [43] [44] Multiple studies report that Gram-negative organisms are responsible for 10%, 45 20%-40%, 46 of HCAIs and that antimicrobial resistance places a significant burden on the global health care system, particularly in low resource countries.”
Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. (2009, background): “New antibacterial agents approved in the United States, 1983–2007, per 5-year period [2, 3].”
Mechanisms of Antimicrobial Resistance in ESKAPE Pathogens (2016, methodology): “Recent reports using data from hospital-based surveillance studies as well as from the Infectious Diseases Society of America have begun to refer to a group of nosocomial pathogens as “ESKAPE pathogens” [3, 4].”
Combating antimicrobial resistance: policy recommendations to save lives. (2011, background): “reasons for such a clinical trial network have been previously emphasized [46].”
Acinetobacter baumannii (2012, positive): “The most common and serious MDR pathogens have been encompassed within the acronym “ESKAPE,” standing for Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp.(7) While in the 1970s A.”
Three Decades of β-Lactamase Inhibitors (2010, background): “The development of antibiotics remains one of the most significant advances in modern medicine (364).”